Gujarat Themis Biosyn Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required.

This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies.

Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.

Powered by Capital Market - Live News

Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 October 2024.

Powered by Capital Market - Live News

This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore.

Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter.

Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24).

Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review.

As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year.

Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O.

The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday.

In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period.

Powered by Capital Market - Live News